Iovance Biotherapeutics Raises 2026 Revenue Guidance
MT newswire2026/09/29 11:21Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
07:21 AM EDT, 09/29/2026 (MT Newswires) -- Iovance Biotherapeutics (IOVA) said Tuesday it raised its full year 2026 total revenue guidance to a range of $410 million to $420 million, from prior outlook of $350 million to $370 million. Analysts polled by FactSet expect $402.8 million. Iovance said the outlook raise is driven by strong US demand for Amtagvi and Proleukin. Shares of the company were up more than 5% pre-bell Tuesday.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
GM President Shrugs Off Near-Record Diesel Prices -- WSJ
Dow Jones•2026/09/29 17:32
Monero Releases New Stressnet Version
UToday•2026/09/29 17:03
